Ascentage Pharma is a biopharmaceutical company developing apoptosis-targeted and other precision oncology drugs. Its pipeline centers on inhibitors that restore programmed cell death in cancer cells, including Bcl-2/Bcl-xL and other apoptosis pathways. The group advances clinical programs for hematologic malignancies and solid tumors and commercializes selected oncology products in China and other markets.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 209.7 | — | -882.9 | — |
| 2023 | 222 | 5.8% | -925.6 | — |
| 2024 | 980.6 | 341.8% | -405.4 | — |
| 2025 | 574.1 | -41.5% | -1,242.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hillman Solutions Corp. (HLMN), Ultragenyx Pharmaceutical Inc. (RARE), Certara, Inc. (CERT), Keel Infrastructure Corp. (KEEL), Westamerica Bancorporation (WABC), Absci Corporation (ABSI)